{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0081172_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"183-816-618-092-807"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10797,"type":"PATENT","title":"University of Pittsburgh - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8047,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8262,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Univ* Pittsburgh\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents:5316
Search Applicants and Owners separately: \"Univ* Pittsburgh\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents:5316
the nucleic acid of claim 1, and\n
a sterile carrier, pharmaceutically acceptable excipient, adjuvant, and/or buffer that is substantially isotonic."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The composition claim 33, wherein the composition is suitable for administration to a mammal."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 34, wherein the mammal is human."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["A composition comprising:\n
the cell of claim 25, and\n
a sterile carrier, pharmaceutically acceptable excipient, adjuvant, and/or buffer that is substantially isotonic."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The composition claim 36, wherein the composition is suitable for administration to a mammal."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 38, wherein the mammal is human."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["A composition comprising:\n
the population of cells of claim 31, and\n
a sterile carrier, pharmaceutically acceptable excipient, adjuvant, and/or buffer that is substantially isotonic."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The composition claim 39, wherein the composition is suitable for administration to a mammal."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 40, wherein the mammal is human."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["A gene delivery vector comprising the nucleic acid of claim 1."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is a viral vector."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the viral vector is a retroviral vector."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is selected from the group consisting of a herpes viral vector, an adenoviral vector, and an adeno-associated viral vector."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is a lentiviral vector."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is an “MFG” vector."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is a non-viral vector."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The gene delivery vector of claim 42, wherein the gene delivery vector is a liposomal vector."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["An isolated or substantially purified receptor encoded by the nucleic acid of claim 1."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The isolated or substantially purified receptor of claim 50, wherein the receptor is soluble."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The isolated or substantially purified receptor of claim 50, wherein the receptor is membrane bound."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["An immunocytochemistry stain comprising the receptor of claim 50 complexed with a labeling agent."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["An immunocytochemistry stain comprising the receptor of claim 51 complexed with a labeling agent."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["An immunocytochemistry stain comprising the receptor of claim 52 complexed with a labeling agent."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["A method of activating a signaling pathway in a cell having a signaling pathway, the method comprising:\n
a. transducing the cell having a signaling pathway with at least one nucleic acid encoding a receptor, wherein the receptor\n\ni. is expressed and displayed on the surface of the transduced cell,\nii. binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC), and\n
b. contacting the transduced cell to a cell expressing the MUC1 tumor antigen thereby activating the signaling pathway."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 57, wherein the receptor is a T cell receptor."],"number":58,"annotation":false,"title":false,"claim":true},{"lines":["A method of activating a signaling pathway in a cell having a signaling pathway, the method comprising:\n
a. transducing the cell having a signaling pathway with at least one nucleic acid encoding a receptor, which comprises the nucleic acid of claim 1, wherein the receptor\n\ni. is expressed and displayed on the surface of the transduced cell,\nii. binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC), and\n
b. contacting the transduced cell to a cell expressing the MUC1 tumor antigen thereby activating the signaling pathway."],"number":59,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 59, wherein the receptor is a T cell receptor."],"number":60,"annotation":false,"title":false,"claim":true},{"lines":["A method of activating a signaling pathway in a cell comprising a signaling pathway, the method comprising transducing the cell with a receptor having affinity for MUC1, wherein the affinity is determined by a first amino acid sequence and a second amino acid sequence, wherein\n
the first amino acid sequence consists essentially of the portion of MA Vα23 shown in FIG. 1 (SEQ ID NO:1), and\n
the second amino acid sequence consists essentially of the portion of MA Vβ8.3 shown in FIG. 1 (SEQ ID NO:2)."],"number":61,"annotation":false,"title":false,"claim":true},{"lines":["A method of killing a cancer cell, the method comprising\n
a. isolating a population of cells comprising a receptor, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC), and\n
b. contacting the isolated population of cells to a cell expressing the MUC1 tumor antigen thereby killing the cancer cell."],"number":62,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 60, wherein the population comprises T cells."],"number":63,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 61, wherein the population consists essentially of T cells."],"number":64,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 62, wherein the population does not comprise cells, other than T cells, that comprise a receptor that binds to a MUC1 tumor antigen independently of a major histocompatibility complex (MHC)."],"number":65,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}